MIDDLE EAST AND AFRICA ALZHEIMER’S DISEASE THERAPEUTICS AND DIAGNOSTICS MARKET 2022-2028
TABLE OF CONTENTS
1. MIDDLE
EAST AND AFRICA ALZHEIMER’S DISEASE THERAPEUTICS AND DIAGNOSTICS MARKET –
SUMMARY
2. INDUSTRY
OUTLOOK
2.1. TIMELINE
OF ALZHEIMER’S DISEASE THERAPEUTICS AND DIAGNOSTICS MARKET
2.2. PHASES
AND STERNNESS OF ALZHEIMER’S DISEASE
2.3. KEY
INSIGHTS
2.3.1. USAGE
OF COMPUTED TOMOGRAPHY FOR THE DIAGNOSIS OF ALZHEIMER’S DISEASE
2.3.2. R&D
INVESTMENTS IN BIOMARKERS FOR EARLY DETECTION OF DEMENTIA
2.3.3. DEMAND
FOR PERSONALIZED MEDICINES
2.4. IMPACT
OF COVID-19 ON THE ALZHEIMER’S DISEASE THERAPEUTICS AND DIAGNOSTICS MARKET
2.5. PORTER’S
FIVE FORCES ANALYSIS
2.6. MARKET
ATTRACTIVENESS MATRIX
2.7. VENDOR
SCORECARD
2.8. INDUSTRY
COMPONENTS
2.8.1. RESEARCH
& DEVELOPMENT (R & D)
2.8.2. RAW
MATERIALS
2.8.3. MANUFACTURING
2.8.4. DISTRIBUTORS/WHOLESALERS/RETAILERS
2.8.5. END-USER
2.9. KEY
IMPACT ANALYSIS
2.9.1. EFFECTIVENESS
2.9.2. PRICE
2.9.3. SAFETY
2.10. KEY
MARKET STRATEGIES
2.10.1. ACQUISITIONS
2.10.2. PRODUCT
LAUNCHES
2.10.3. CONTRACTS
& AGREEMENTS
2.10.4. INVESTMENTS
& EXPANSIONS
2.11. MARKET
DRIVERS
2.11.1. PREVALENCE
OF ALZHEIMER’S DISEASE
2.11.2. RISE
IN THE ELDERLY POPULATION
2.12. MARKET
CHALLENGES
2.12.1. FAILURE
OF LATE-STAGE DRUGS
2.12.2. STRINGENT
GOVERNMENT REGULATIONS
2.13. MARKET
OPPORTUNITIES
2.13.1. EMERGENCE
OF NEW DIAGNOSTIC TECHNOLOGIES
2.13.2. GROWING
NUMBER OF PIPELINE DRUGS
3. MIDDLE
EAST AND AFRICA ALZHEIMER’S DISEASE THERAPEUTICS AND DIAGNOSTICS MARKET – BY
THERAPEUTICS
3.1. BY
DRUG TYPE
3.1.1. MARKETED
DRUGS
3.1.2. PIPELINE
DRUGS
3.2. BY
DISEASE STAGE
3.2.1. LATE
STAGE: SEVERE AD
3.2.2. EARLY/MIDDLE
STAGE: MILD TO MODERATE AD
3.2.3. PRODROMAL
STAGE
3.3. BY
GENERIC & BRANDED
3.3.1. BRANDED
3.3.2. GENERIC
4. MIDDLE
EAST AND AFRICA ALZHEIMER’S DISEASE THERAPEUTICS AND DIAGNOSTICS MARKET – BY
DIAGNOSTICS
4.1. LUMBAR
PUNCTURE TEST
4.2. POSITRON
EMISSION TOMOGRAPHY
4.3. ELECTROENCEPHALOGRAPHY
4.4. MAGNETIC
RESONANCE IMAGING
4.5. COMPUTED
TOMOGRAPHY
4.6. BLOOD
TEST
4.7. OTHER
DIAGNOSTICS
5. MIDDLE
EAST AND AFRICA ALZHEIMER’S DISEASE THERAPEUTICS AND DIAGNOSTICS MARKET –
COUNTRY OUTLOOK
5.1. UNITED
ARAB EMIRATES
5.2. TURKEY
5.3. SAUDI
ARABIA
5.4. SOUTH
AFRICA
5.5. REST
OF MIDDLE EAST & AFRICA
6. COMPETITIVE
LANDSCAPE
6.1. BAXTER
INTERNATIONAL INC
6.2. F.
HOFFMANN-LA ROCHE AG
6.3. ALLERGAN
PLC (ACQUIRED BY ABBVIE)
6.4. NOVARTIS
AG
6.5. PFIZER
INC
6.6. SIEMENS
HEALTHINEERS AG
6.7. AMARANTUS
BIOSCIENCE HOLDINGS INC
6.8. EISAI
CO LTD
6.9. ELI
LILLY & COMPANY
6.10. LUPIN
LIMITED
6.11. MERCK
AND CO
6.12. BIOGEN
INC
6.13. COGNOPTIX
INC
6.14. GE
HEALTHCARE
6.15. JOHNSON
AND JOHNSON
6.16. SUN
PHARMACEUTICALS INDUSTRIES LTD
6.17. TEVA
PHARMACEUTICAL INDUSTRIES LTD
6.18. ZYDUS
CADILA
7. METHODOLOGY
& SCOPE
7.1. RESEARCH
SCOPE
7.2. SOURCES
OF DATA
7.3. RESEARCH
METHODOLOGY
TABLE
LIST
TABLE 1: MIDDLE EAST AND
AFRICA ALZHEIMER’S DISEASE THERAPEUTICS AND DIAGNOSTICS MARKET, COUNTRY
OUTLOOK, 2022-2028 (IN $ MILLION)
TABLE 2: MARKET ATTRACTIVENESS
MATRIX
TABLE 3: VENDOR SCORECARD
TABLE 4: KEY STRATEGIC
DEVELOPMENTS
TABLE 5: MIDDLE EAST AND
AFRICA ALZHEIMER’S DISEASE THERAPEUTICS AND DIAGNOSTICS MARKET, BY
THERAPEUTICS, 2022-2028 (IN $ MILLION)
TABLE 6: MIDDLE EAST AND
AFRICA ALZHEIMER’S DISEASE THERAPEUTICS MARKET, BY DRUG TYPE, 2022-2028 (IN $
MILLION)
TABLE 7: MIDDLE EAST AND
AFRICA ALZHEIMER’S DISEASE THERAPEUTICS MARKET, BY DISEASE STAGE, 2022-2028 (IN
$ MILLION)
TABLE 8: MIDDLE EAST AND
AFRICA ALZHEIMER’S DISEASE THERAPEUTICS MARKET, BY GENERIC & BRANDED,
2022-2028 (IN $ MILLION)
TABLE 9: MIDDLE EAST AND
AFRICA ALZHEIMER’S DISEASE THERAPEUTICS AND DIAGNOSTICS MARKET, BY DIAGNOSTICS,
2022-2028 (IN $ MILLION)
TABLE 10: MIDDLE EAST AND
AFRICA ALZHEIMER’S DISEASE THERAPEUTICS AND DIAGNOSTICS MARKET, COUNTRY
OUTLOOK, 2022-2028 (IN $ MILLION)
FIGURE
LIST
FIGURE 1: PORTER’S FIVE
FORCES ANALYSIS
FIGURE 2: KEY IMPACT
ANALYSIS
FIGURE 3: TIMELINE OF
ALZHEIMER’S DISEASE THERAPEUTICS AND DIAGNOSTICS
FIGURE 4: INDUSTRY
COMPONENTS
FIGURE 5: MIDDLE EAST
AND AFRICA ALZHEIMER’S DISEASE THERAPEUTICS AND DIAGNOSTICS MARKET, BY
THERAPEUTICS, 2021 & 2028 (IN %)
FIGURE 6: MIDDLE EAST
AND AFRICA ALZHEIMER’S DISEASE THERAPEUTICS MARKET, BY DRUG TYPE, 2021 &
2028 (IN %)
FIGURE 7: MIDDLE EAST
AND AFRICA ALZHEIMER’S DISEASE THERAPEUTICS MARKET, BY MARKETED DRUGS,
2022-2028 (IN $ MILLION)
FIGURE 8: MIDDLE EAST
AND AFRICA ALZHEIMER’S DISEASE THERAPEUTICS MARKET, BY PIPELINE DRUGS,
2022-2028 (IN $ MILLION)
FIGURE 9: MIDDLE EAST
AND AFRICA ALZHEIMER’S DISEASE THERAPEUTICS MARKET, BY DISEASE STAGE, 2021
& 2028 (IN %)
FIGURE 10: MIDDLE EAST
AND AFRICA ALZHEIMER’S DISEASE THERAPEUTICS MARKET, BY LATE STAGE: SEVERE AD,
2022-2028 (IN $ MILLION)
FIGURE 11: MIDDLE EAST
AND AFRICA ALZHEIMER’S DISEASE THERAPEUTICS MARKET, BY EARLY/MIDDLE STAGE: MILD
TO MODERATE AD, 2022-2028 (IN $ MILLION)
FIGURE 12: MIDDLE EAST
AND AFRICA ALZHEIMER’S DISEASE THERAPEUTICS MARKET, BY PRODROMAL STAGE,
2022-2028 (IN $ MILLION)
FIGURE 13: MIDDLE EAST
AND AFRICA ALZHEIMER’S DISEASE THERAPEUTICS MARKET, BY GENERIC & BRANDED,
2021 & 2028 (IN %)
FIGURE 14: MIDDLE EAST
AND AFRICA ALZHEIMER’S DISEASE THERAPEUTICS MARKET, BY BRANDED, 2022-2028 (IN $
MILLION)
FIGURE 15: MIDDLE EAST
AND AFRICA ALZHEIMER’S DISEASE THERAPEUTICS MARKET, BY GENERIC, 2022-2028 (IN $
MILLION)
FIGURE 16: MIDDLE EAST
AND AFRICA ALZHEIMER’S DISEASE THERAPEUTICS AND DIAGNOSTICS MARKET, BY
DIAGNOSTICS, 2021 & 2028 (IN %)
FIGURE 17: MIDDLE EAST
AND AFRICA ALZHEIMER’S DISEASE DIAGNOSTICS MARKET, BY LUMBAR PUNCTURE TEST,
2022-2028 (IN $ MILLION)
FIGURE 18: MIDDLE EAST
AND AFRICA ALZHEIMER’S DISEASE DIAGNOSTICS MARKET, BY POSITRON EMISSION
TOMOGRAPHY, 2022-2028 (IN $ MILLION)
FIGURE 19: MIDDLE EAST
AND AFRICA ALZHEIMER’S DISEASE DIAGNOSTICS MARKET, BY ELECTROENCEPHALOGRAPHY,
2022-2028 (IN $ MILLION)
FIGURE 20: MIDDLE EAST
AND AFRICA ALZHEIMER’S DISEASE DIAGNOSTICS MARKET, BY MAGNETIC RESONANCE
IMAGING, 2022-2028 (IN $ MILLION)
FIGURE 21: MIDDLE EAST
AND AFRICA ALZHEIMER’S DISEASE DIAGNOSTICS MARKET, BY COMPUTED TOMOGRAPHY,
2022-2028 (IN $ MILLION)
FIGURE 22: MIDDLE EAST
AND AFRICA ALZHEIMER’S DISEASE DIAGNOSTICS MARKET, BY BLOOD TEST, 2022-2028 (IN
$ MILLION)
FIGURE 23: MIDDLE EAST
AND AFRICA ALZHEIMER’S DISEASE DIAGNOSTICS MARKET, BY OTHER DIAGNOSTICS,
2022-2028 (IN $ MILLION)
FIGURE 24: MIDDLE EAST
AND AFRICA ALZHEIMER’S DISEASE THERAPEUTICS AND DIAGNOSTICS MARKET, COUNTRY
OUTLOOK, 2021 & 2028 (IN %)
FIGURE 25: UNITED ARAB
EMIRATES ALZHEIMER’S DISEASE THERAPEUTICS AND DIAGNOSTICS MARKET 2022-2028 (IN
$ MILLION)
FIGURE 26: SAUDI ARABIA
ALZHEIMER’S DISEASE THERAPEUTICS AND DIAGNOSTICS MARKET 2022-2028 (IN $
MILLION)
FIGURE 27: TURKEY
ALZHEIMER’S DISEASE THERAPEUTICS AND DIAGNOSTICS MARKET 2022-2028 (IN $
MILLION)
FIGURE 28: SOUTH AFRICA
ALZHEIMER’S DISEASE THERAPEUTICS AND DIAGNOSTICS MARKET 2022-2028 (IN $
MILLION)
FIGURE 29: REST OF
MIDDLE EAST & AFRICA ALZHEIMER’S DISEASE THERAPEUTICS AND DIAGNOSTICS
MARKET 2022-2028 (IN $ MILLION)
The expected surge in the elderly population is expected to
influence the market growth in the Middle East and Africa
MARKET OUTLOOK
Triton Market Research
estimates that the Alzheimer’s disease therapeutics and diagnostics market in
the Middle East and Africa would progress with a CAGR of 5.81% over the
forecasting years 2022-2028. Turkey, the United Arab Emirates, Saudi Arabia,
South Africa, and Rest of Middle East & Africa are scrutinized in the
market in this region.
Egypt, Qatar, Uganda,
Israel, Iran, Nigeria, Kenya, and other countries are included in the Rest of
Middle East & Africa region. According to the World Population Ageing 2019 report,
there were nearly 5.2729 million people in Iran who were aged 65 years or older
in 2019. And by 2050, this elderly population is expected to rise to 20.78
million people. The market for AD therapeutics and diagnostics is anticipated
to grow in the near future owing to the expected increase in the elderly population
and the fact that this demographic is more vulnerable to neurological illnesses
like Alzheimer’s disease and dementia.
According to estimates
from the World Population Ageing 2019 report, nearly 3.171 million people in
South Africa were aged 65 or above, as of 2019. By 2050, approximately 7.920
million people are expected to constitute this age group. This is expected to increase
the number of Alzheimer’s patients as well. The increased patient pool is also
likely to draw the attention of market players to innovate and offer better
treatment options for patients. Thus, owing to the growing prevalence of the
disease, an increase in the aging population, and the development of advanced
technologies for the diagnosis and treatment of Alzheimer’s, the market for AD
therapeutics and diagnostics in South Africa is anticipated to flourish over
the coming years.
Get more insights the Middle East and Africa Alzheimer’s Disease Therapeutics And
Diagnostic Market:
COMPETITIVE OUTLOOK
Zydus Cadila, Siemens
Healthineers AG, Eli Lilly & Company, Baxter International Inc, GE
Healthcare, F. Hoffmann-La Roche AG, Sun Pharmaceuticals Industries Ltd, Teva
Pharmaceutical Industries Ltd, and Johnson and Johnson are some of the
prominent companies operating in the Alzheimer’s disease therapeutics and
diagnostics market.
SEGMENTATION
1. BAXTER
INTERNATIONAL INC
2. F.
HOFFMANN-LA ROCHE AG
3. ALLERGAN
PLC (ACQUIRED BY ABBVIE)
4. NOVARTIS
AG
5. PFIZER
INC
6. SIEMENS
HEALTHINEERS AG
7. AMARANTUS
BIOSCIENCE HOLDINGS INC
8. EISAI
CO LTD
9. ELI
LILLY & COMPANY
10. LUPIN
LIMITED
11. MERCK
AND CO
12. BIOGEN
INC
13. COGNOPTIX
INC
14. GE
HEALTHCARE
15. JOHNSON
AND JOHNSON
16. SUN
PHARMACEUTICALS INDUSTRIES LTD
17. TEVA
PHARMACEUTICAL INDUSTRIES LTD
18. ZYDUS
CADILA
Comments
Post a Comment